Acute myelogenous leukemia (AML) is seen in this stock image. Duke researchers have discovered a new combination of drugs ...

Actinium Pharmaceuticals (ATNM) has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center to expand ...

The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who ...

CERo’s technology works by grafting onto patients’ own T-cells a receptor that binds to a naturally occurring human antigen ...

Researchers from Karl Landsteiner University of Health Sciences (KL Krems) have discovered that combining two existing drugs ...

Aptevo Therapeutics reports strong remission rates in AML patients using mipletamig plus ven/aza, with Cohort 2 enrollment ...

Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...

Anthony Stein, MD, assessed total marrow and lymphoid irradiation with post-transplant cyclophosphamide in patients with ...

Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical ...